Loading…
Orchestra BioMed Holdings, Inc. is projected to rise to $4.72 by 2027, a +18% move from its current price of $3.99. OBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.86 | $3.99 | $4.12 | +0.03% |
| Jul 14 | $3.81 | $3.99 | $4.18 | +0.05% |
| Jul 15 | $3.77 | $3.99 | $4.23 | +0.08% |
| Jul 16 | $3.74 | $3.99 | $4.26 | +0.11% |
| Jul 17 | $3.71 | $4.00 | $4.30 | +0.13% |
| Jul 18 | $3.69 | $4.00 | $4.33 | +0.16% |
| Jul 19 | $3.67 | $4.00 | $4.36 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.67 | $4.00 | $4.36 | +0.18% |
| Week 2 | $3.54 | $4.00 | $4.52 | +0.37% |
| Week 3 | $3.46 | $4.01 | $4.66 | +0.55% |
| Week 4 | $3.38 | $4.02 | $4.78 | +0.74% |
| Week 5 | $3.32 | $4.03 | $4.88 | +0.92% |
| Week 6 | $3.27 | $4.03 | $4.98 | +1.11% |
| Week 7 | $3.22 | $4.04 | $5.08 | +1.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.
It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc.
for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Orchestra BioMed Holdings, Inc. (OBIO) is a healthcare-focused biomedical company with a portfolio of bioelectronic therapies and medical devices. The stock is currently priced at $3.96 with a market capitalization of $237.13M, and it ranks 3705 by market cap.
The current price and market position sit within a broader forecast that envisions multiple years of rising averages, culminating in substantially higher projections later in the horizon.
A major floor 18.0% below — a decisive break under it would weaken the trend.
The nearest floor, 4.0% below — buyers have tended to step in here.
The nearest ceiling, 19.0% above — a clean break opens room to run.
A major ceiling 28.1% above — clearing it would confirm fresh momentum.
Key OBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.97 | Buy | $4.00 | Sell |
| MA 10 | $4.17 | Sell | $4.05 | Sell |
| MA 20 | $4.08 | Sell | $4.06 | Sell |
| MA 50 | $4.01 | Sell | $4.07 | Sell |
| MA 100 | $4.17 | Sell | $4.09 | Sell |
| MA 200 | $4.07 | Sell | $4.05 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.62 | Neutral |
| Stoch RSI (14) | 9.27 | Buy |
| CCI (20) | -39.45 | Neutral |
| Williams %R (14) | -89.41 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -1.24 | Sell |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 10.59 | Buy |
| TRIX (15) | 0.12 | Buy |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 30.22 | Neutral |
| Momentum (10) | 0.09 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 3.84 | Buy |
| ADX (14) | 9.15 | Neutral |
| ATR (14) | 0.11 | Info |
Technically, the picture is bearish at the moment. The RSI(14) is 50, suggesting neither overbought nor oversold conditions. The near-term moving averages are $4.02 for the SMA50 and $4.05 for the SMA200, indicating a tight range around the current level.
Support sits at $3.83 and resistance at $4.75, with a 30-day price range of $3.13 to $5.00. The stock exhibits high volatility, with annualized volatility at 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.49 | $3.99 | $5.48 | 0% | Neutral | |
| $3.69 | $4.72 | $6.43 | +18% | Neutral | |
| $4.38 | $5.80 | $8.25 | +45% | Bullish | |
| $4.81 | $6.55 | $9.63 | +64% | Bullish | |
| $4.46 | $6.23 | $9.42 | +56% | Bullish | |
| $4.73 | $6.76 | $10.47 | +69% | Bullish | |
| $4.78 | $6.98 | $11.05 | +75% | Bullish | |
| $4.77 | $7.10 | $11.47 | +78% | Bullish | |
| $6.30 | $9.57 | $15.73 | +140% | Bullish | |
| $6.69 | $10.35 | $17.30 | +159% | Bullish | |
| $8.50 | $14.32 | $25.67 | +259% | Bullish | |
| $11.71 | $22.94 | $45.47 | +475% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.49 | $3.99 | $4.85 | +0.00% |
| August 2026 | $3.52 | $4.17 | $5.10 | +4.62% |
| September 2026 | $3.42 | $4.09 | $5.06 | -2.10% |
| October 2026 | $3.32 | $4.00 | $5.01 | -2.00% |
| November 2026 | $3.44 | $4.18 | $5.28 | +4.26% |
| December 2026 | $3.52 | $4.30 | $5.48 | +2.91% |
Click any year to see its month-by-month OBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect OBIO to range from $3.49 to $5.48 through 2026. The $3.99 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The OBIO price prediction for 2027 points to an average of $4.72 (low $3.69, high $6.43) — a potential gain of +18% on today's $3.99. A consolidation phase looks the most probable path here.
In 2028, OBIO is projected to trade between $4.38 and $8.25, averaging $5.80 — a potential gain of +45% from today's $3.99. That is up +23% on the projected 2027 average. Momentum favours further upside here.
Orchestra BioMed Holdings, Inc.'s 2029 outlook centres on $6.55, within a $4.81 to $9.63 range. That is up +13% on the projected 2028 average. That marks a +64% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, OBIO could reach as high as $9.42, with a base case around $6.23 and support toward $4.46 — roughly +56% from $3.99. Momentum favours further upside here.
Expect OBIO to range from $4.73 to $10.47 through 2031. The $6.76 average target implies a +69% move from current prices. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The OBIO price prediction for 2032 points to an average of $6.98 (low $4.78, high $11.05) — a potential gain of +75% on today's $3.99. Momentum favours further upside here.
In 2033, OBIO is projected to trade between $4.77 and $11.47, averaging $7.10 — a potential gain of +78% from today's $3.99. That is up +2% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Orchestra BioMed Holdings, Inc.'s 2034 outlook centres on $9.57, within a $6.30 to $15.73 range. That is up +35% on the projected 2033 average. That marks a +140% change versus current levels. Momentum favours further upside here.
By 2035, OBIO could reach as high as $17.30, with a base case around $10.35 and support toward $6.69 — roughly +159% from $3.99. Buyers look set to stay in control over this stretch.
Expect OBIO to range from $8.50 to $25.67 through 2040. The $14.32 average target implies a +259% move from current prices. That is up +38% on the projected 2035 average. Momentum favours further upside here.
The OBIO price prediction for 2050 points to an average of $22.94 (low $11.71, high $45.47) — a potential gain of +475% on today's $3.99. Buyers look set to stay in control over this stretch.
Investing $1,000 in OBIO today (≈ 250.626566 OBIO) could be worth
$5,749.66
+$4,749.66 (+475%) by 2050 · US Dollar
Based on the average projected OBIO price of $22.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OBIOwould be worth at today's price.
$1,000 invested in OBIO on Jul 10, 2025 (≈ 333.333333 OBIO) would be worth
$1,330
+$330 (+33.0%) today · 1.33× · US Dollar
Based on a OBIO entry price of $3 vs. today's $3.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.19 | $952.27 | -4.8% |
| 1 month ago | $4.02 | $992.54 | -0.7% |
| 3 months ago | $4.13 | $966.1 | -3.4% |
| 6 months ago | $4.66 | $856.22 | -14.4% |
| 1 year ago | $3 | $1,330 | +33.0% |
| All time (5.0y) ago | $9.95 | $401.01 | -59.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OBIO forecast.
Our base-case forecast reaches $8.00 around 2034.
Implied market cap at $8.00: $479.05M
The multi-year forecast shows a rising trajectory, with the average price projected from $3.96 in 2026 to $23.11 by 2050. Key milestones include 2027 avg $4.73 and 2028 avg $5.89, with 2030 avg $6.26 and 2034 avg $9.83. By 2040, the average is projected to reach $14.73, and by 2050 the average is $23.11.
ROI progresses from 0% in 2026 to 19.5% in 2027, then to 58.2% in 2030, 272.1% by 2040, and 483.6% by 2050. The forecast also assigns bullish sentiment from 2028 onward, after a neutral stance in 2026 and 2027. These figures are estimates and not guarantees, reflecting potential upside under the model’s assumptions.
Tap a question to reveal the answer.
For 2030, the forecast shows min $4.40, avg $6.26, max $9.66, with a projected ROI of 58.2% and a bullish sentiment.
The forecast envisions a rising average price path with a transition from neutral in 2026–2027 to bullish from 2028 onward. The 2030–2050 averages rise to $6.26, $14.73, and $23.11 respectively, with ROI reaching up to 483.6% by 2050. These are estimates, not guarantees.
Yes. The 2034 forecast shows min $6.29, avg $9.83, max $16.58, with a bullish overall path. Reaching or exceeding $10 by 2034 is within the projected range.
The current price is $3.96 and the market capitalization is $237.13M. The company ranks 3705 by market cap.
The 30-day range is $3.13 to $5.00. The RSI(14) is 50, with a 50-day view around $4.02 for the SMA50 and $4.05 for the SMA200. Support is at $3.83 and resistance at $4.75, reflecting a cautious intermediate outlook.
Orchestra BioMed Holdings, Inc. Community Discussion
0Share your Orchestra BioMed Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.